Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow (Nasdaq: HROW) will report first quarter 2026 financial results for the period ended March 31, 2026, on Monday, May 11, 2026 after market close. The company will post a Letter to Stockholders on its Investors page at harrow.com.
Harrow will host a live webcast and conference call at 8:00 a.m. ET on Tuesday, May 12, 2026 to discuss results and provide a business update. Telephone participants must register in advance to receive a unique dial-in number and PIN. A replay of the webcast will be available on the company website for one year.
Harrow (Nasdaq: HROW) announced that IOPIDINE 1% (apraclonidine) received a permanent J-Code J2374, enabling in-office reimbursement effective July 1, 2026. The designation removes a practical barrier to routine office use and is expected to support broader adoption for prophylactic IOP management during ophthalmic laser procedures.
IOPIDINE 1% has shown a reduction in severe post-procedure IOP spikes from ~23% to ~2% (~91% relative reduction). The company highlights a large addressable base—>4 million glaucoma patients and >1.5 million annual ophthalmic laser procedures in the U.S.
Harrow (Nasdaq: HROW) has selected LogiCare3PL as its U.S. distribution partner for Harrow's ophthalmic disease management solutions. Effective Feb 1, 2026, LogiCare3PL will provide both non-title logistics and 3PL title distribution across the U.S., meeting Harrow's rapid onboarding needs.
LogiCare3PL completed Harrow's onboarding in four weeks, supporting faster, cost-effective market access while maintaining high-touch customer engagement and continuity of supply.
Harrow (Nasdaq: HROW) priced a private offering of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due September 15, 2030. The notes will be issued at 100.25% and treated as a single series with an existing $250.0 million 2030 note issue.
The offering is expected to close on March 27, 2026, interest accrues from March 15, 2026, and net proceeds are for general corporate purposes including product development and growth initiatives.
Harrow (Nasdaq: HROW) intends to offer an additional $50.0 million aggregate principal of its 8.625% senior unsecured notes due 2030 as an add-on to the existing $250.0 million series issued Sept 12, 2025.
Proceeds are planned for general corporate purposes, including product launches, development, and strategic opportunities; the offering targets qualified institutional buyers and non-U.S. persons under Regulation S.
Harrow (Nasdaq: HROW) announced three scientific abstracts accepted for presentation at the ASCRS 2026 Annual Meeting, April 10–13 in Washington, D.C. The studies feature Harrow commercial products VEVYE 0.1% and ILEVRO 0.3% covering dry eye disease and post-cataract surgery outcomes.
Presentations occur April 11–12 and will release detailed data at session times listed by the company.
Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida. The management presentation will be webcast live on the company website, with a replay available for approximately 90 days after the event.
Harrow (Nasdaq: HROW) announced FDA clearance of an IND to support a planned Phase 3 trial of TRIESENCE 40 mg/mL for ocular inflammation and pain following cataract surgery. The randomized, placebo-controlled, double-masked study will enroll ~250 patients (2:1 randomization) with primary endpoints at Day 14 (anterior chamber cells) and Day 8 (pain).
Harrow expects study initiation in Q1 2026 and enrollment to start in Q2 2026, aiming to generate data to potentially expand TRIESENCE’s label and strengthen its surgical care role.
Harrow (Nasdaq: HROW) reported record Q4 revenue of $89.1M (up 33% YoY) and full-year 2025 revenue of $272.3M (up 36% YoY). GAAP net income was $6.6M in Q4 while full-year GAAP showed a $5.1M net loss. Adjusted EBITDA was $24.2M in Q4 and $61.9M for 2025. Harrow generated $43.9M operating cash flow in 2025 and ended the year with $72.9M cash. 2026 guidance: revenue $350M–$365M and Adjusted EBITDA $80M–$100M.
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.